JW Pharmaceutical headquarters. [JW Pharmaceutical]
JW Pharmaceutical headquarters. [JW Pharmaceutical]

JW Pharmaceutical is celebrating a double milestone: record quarterly earnings built on a robust prescription drug portfolio, and a successful Phase 3 clinical trial for its internally developed gout treatment candidate. The results mark a visible payoff from the company's strategy of channeling stable cash flows from its originator drug lineup into intensive new drug research and development.

The company said its multinational Phase 3 trial of epaminurad (code name URC102), a gout treatment candidate, showed that the drug's primary dose of 6 mg was statistically superior to the standard-of-care febuxostat 40 mg. Conducted across 52 institutions in five Asian countries — South Korea, Taiwan, Thailand, Malaysia and Singapore — the trial enrolled 612 gout patients. The epaminurad 6 mg group achieved a serum uric acid level below 6 mg/dL in 50.0% of patients, the primary efficacy endpoint, outpacing the control group's 38.3% by 12.0 percentage points. The drug also demonstrated a favorable safety profile comparable to febuxostat, with no drug-related deaths or notable adverse events.

Gout is a chronic metabolic disease in which abnormally elevated blood uric acid levels cause urate crystals to deposit in joints and surrounding tissue, triggering severe episodic pain and inflammation. Rising rates of Westernized diets, frequent alcohol consumption and obesity have driven a sharp increase in the patient population. According to the Health Insurance Review and Assessment Service, the number of gout patients in South Korea grew more than 18 percent in four years, from about 468,000 in 2020 to more than 553,000 in 2024.

The global market is expanding just as rapidly. According to market research firm Grand View Research, the global gout treatment market is projected to grow from about $2.8 billion in 2024 to about $4.1 billion by 2030.

Despite this market expansion, unmet medical need at the clinical level remains significant. Gout stems from an imbalance between uric acid production and excretion in the body, and is broadly classified into two types: underexcretion, in which the kidneys fail to eliminate enough uric acid, and overproduction, in which the body synthesizes excessive amounts.

While 80 to 90 percent of patients fall into the underexcretion category, existing uricosuric agents have faced prescribing restrictions due to safety concerns including liver toxicity and severe kidney damage. As a result, clinicians have had to rely on xanthine oxidase inhibitors — febuxostat or allopurinol — even for underexcretion patients, despite those drugs targeting a different mechanism. That dynamic explains why febuxostat accounts for 84.4%, or about 34.7 billion won, of South Korea's domestic gout treatment market, which pharmaceutical market research firm Ubist valued at about 41.1 billion won ($29 million) in 2025.

Epaminurad works by selectively inhibiting the human urate transporter 1 (hURAT1), which is responsible for uric acid reabsorption in the kidneys, thereby promoting excretion. The drug addresses the liver and kidney toxicity concerns that have long plagued existing uricosuric agents, while demonstrating superiority in a head-to-head trial against febuxostat 40 mg — the standard prescription dose accounting for more than 63 percent of the domestic market. The company said it has scientifically established epaminurad's credentials as a best-in-class drug that directly targets the root cause of gout in the majority of patients.

Livarojet, a combination drug for dyslipidemia. [JW Pharmaceutical]
Livarojet, a combination drug for dyslipidemia. [JW Pharmaceutical]

Underpinning the drug pipeline's progress is strong earnings growth in the company's core business. JW Pharmaceutical posted second-quarter sales of 220.3 billion won and operating profit of 33.7 billion won on a separate basis, up 16.1 percent and 32.7 percent, respectively, from the same period a year earlier. The operating profit margin reached 15.3 percent.

The growth was driven by the company's originator prescription drug lineup, led by Livarojet, a combination therapy for dyslipidemia. The Livalo family generated 53.2 billion won in prescription sales in the second quarter alone, while high-dose intravenous iron injection Ferinject surged 90.1 percent year-on-year to 8.1 billion won. Benign prostatic hyperplasia treatment Trupass brought in 4 billion won, and the intravenous solutions segment — including total parenteral nutrition product Winuf — contributed 72.4 billion won, with all business divisions posting double-digit growth.

The results have reinforced what analysts describe as a virtuous cycle in which stable cash generated from prescription drugs and IV solutions is reinvested into new drug R&D. Epaminurad has been selected as a pilot project under the Ministry of Food and Drug Safety's new drug approval and review innovation initiative. The company is now preparing a new drug application targeting domestic approval in 2027, and discussions on global licensing-out deals are expected to gain momentum.

"The unmet market need for new treatment options is very high, given the growing number of gout patients at home and abroad and safety concerns surrounding existing therapies," said Ham Eun-kyung, chief executive of JW Pharmaceutical. "Having demonstrated superior efficacy and safety compared with febuxostat 40 mg — the most widely prescribed gout drug in South Korea — we will focus all our capabilities on preparing the approval process without delay and establishing epaminurad as a globally innovative drug."


silverpaper@heraldcorp.com